Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 6/20 | 0.39 |
| ▸ | AURKA | O14965 | 5/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | FLT3 | P36888 | 4/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
| ▸ | LYN | P07948 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | BLK | P51451 | 3/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.37 |
| ▸ | STK3 | Q13188 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.37 |
| ▸ | FYN | P06241 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | MARK3 | P27448 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22676019 | 0.85 | AURKA (0.41) | AURKBAURKARXFP1KDRFLT3 | |
| SCHEMBL22678055 | 0.83 | KDR (0.46) | AURKBAURKAKDRFLT3FGFR1 | |
| SCHEMBL22676167 | 0.80 | ATR (0.41) | AURKAKDRFLT3FGFR1NTRK1 | |
| SCHEMBL22676439 | 0.79 | ATR (0.41) | FLT3CYP3A4CDK8CCNC | |
| SCHEMBL22677013 | 0.79 | KIT (0.45) | AURKBAURKARXFP1KDRFLT3 | |
| SCHEMBL22676168 | 0.79 | ALDH1A1 (0.42) | CYP3A4CYP2C9MAPK1 | |
| SCHEMBL22676715 | 0.78 | AURKA (0.47) | AURKBAURKAKDRCDK8TYRO3 | |
| SCHEMBL22676440 | 0.78 | AURKA (0.37) | AURKBAURKAKDRFLT3FGFR1 | |
| SCHEMBL22677323 | 0.77 | KIT (0.44) | RXFP1FGFR1FGFR3KITBAZ1A | |
| SCHEMBL29452462 | 0.77 | FGFR1 (0.42) | AURKBAURKAKDRFLT3FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12522605-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119874707-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114126620-B | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3968999-B1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| EP-3968999-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114126620-A | FGFR inhibitors and methods of use thereof | 传达治疗有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | AURKB 49/4885AURKA 449/4885RXFP1 2354/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | AURKB 49/4885AURKA 449/4885RXFP1 2354/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | AURKB 49/4885AURKA 449/4885RXFP1 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.